What Happened? Shares of lab services company Charles River Laboratories (NYSE:CRL) jumped 7.5% in the morning session after ...

Shares of Charles River Laboratories International Inc. advanced 9.06% to $163.36 Tuesday, on what proved to be an all-around ...

Charles River Laboratories is poised to announce its second-quarter results next month, and analysts predict a double-digit ...

Charles River Laboratories is down 10% during the same time and is heading into earnings with an average analyst price target of $193.34 (compared to the current share price of $151.10).

Charles River Labs seeks support for merger with WuXi Facing opposition over its $1.6 billion merger with WuXi Pharmatech, Charles River Laboratories International is wooing support for the deal ...

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and ...

Charles River Laboratories International, Inc. today reported its results for the third quarter of 2023. For the quarter, revenue was $1.03 billion, an increase of 3.8% from $989.2 million in the ...

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it will appoint Flavia H. Pease as its next Chief Financial Officer, succeeding ...

Charles River announces long-term solar contract for North American operations, moves closer to goal of sourcing 100% renewable electricity by 2030.

Charles River Laboratories International, Inc. announced today that it has acquired Retrogenix Limited, an early-stage contract research organization providing specialized bioanalytical services ...

Charles River Laboratories is parting ways with two divisions for about $115 million, including a Swedish contract developer and manufacturer site snagged in the $875 million acquisition of Cognate ...